179 related articles for article (PubMed ID: 37978838)
1. GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against
Machado MP; Dos Santos MH; Guimarães JG; de Campos GY; Oliveira Brito PKM; Ferreira CMG; Rezende CP; Frota NF; Soares SG; Kumaresan PR; Lourenzoni MR; da Silva TA
Bioengineered; 2023 Dec; 14(1):2281059. PubMed ID: 37978838
[TBL] [Abstract][Full Text] [Related]
2. Modification of Hinge/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to
Dos Santos MH; Machado MP; Kumaresan PR; da Silva TA
Cells; 2022 Oct; 11(21):. PubMed ID: 36359781
[TBL] [Abstract][Full Text] [Related]
3. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
[TBL] [Abstract][Full Text] [Related]
4. Titan Cells and Yeast Forms of
Dos Santos MH; Machado MP; Kumaresan PR; da Silva TA
Microorganisms; 2021 Sep; 9(9):. PubMed ID: 34576780
[TBL] [Abstract][Full Text] [Related]
5. A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.
Bowen A; Wear MP; Cordero RJ; Oscarson S; Casadevall A
J Biol Chem; 2017 Jan; 292(2):417-434. PubMed ID: 27872188
[TBL] [Abstract][Full Text] [Related]
6. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
7. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
8. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G
Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226
[TBL] [Abstract][Full Text] [Related]
9. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
12.
Gonçalves DS; Rodriguez de La Noval C; Ferreira MDS; Honorato L; Araújo GRS; Frases S; Pizzini CV; Nosanchuk JD; Cordero RJB; Rodrigues ML; Peralta JM; Nimrichter L; Guimarães AJ
Front Cell Infect Microbiol; 2020; 10():565571. PubMed ID: 33585262
[TBL] [Abstract][Full Text] [Related]
13. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
Yauch LE; Lam JS; Levitz SM
PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
[TBL] [Abstract][Full Text] [Related]
14. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter.
Fonseca FL; Nohara LL; Cordero RJ; Frases S; Casadevall A; Almeida IC; Nimrichter L; Rodrigues ML
Infect Immun; 2010 Sep; 78(9):3861-70. PubMed ID: 20547742
[TBL] [Abstract][Full Text] [Related]
16. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
19. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
